Search | European Medicines Agency (EMA) (original) (raw)

INN or common name: levamisole

Associated names: Decaris; Levamisol Arena

Status: CMDh final position

Type: Article 31 referrals

CMDh position date: 26 March 2026

Last updated: 13 May 2026

ReferralHuman

INN or common name: ranibizumab

Therapeutic area (MeSH): Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization

Marketing authorisation issued: 22 January 2007

Last updated: 13 May 2026

Revision: 48

MedicineHumanAuthorised

Active substance: tecovirimat monohydrate

DHPC type: Restriction of indication

Last updated: 13 May 2026

DHPCHuman

Active substance: cenobamate

DHPC type: Adverse event, Post-authorisation measure

Last updated: 13 May 2026

DHPCHuman

INN or common name: ponatinib

Therapeutic area (MeSH): Leukemia, Myeloid; Leukemia, Lymphoid

Marketing authorisation issued: 1 July 2013

Last updated: 13 May 2026

Revision: 29

MedicineHumanAuthorised

INN or common name: pegcetacoplan

Therapeutic area (MeSH): Hemoglobinuria, Paroxysmal

Marketing authorisation issued: 13 December 2021

Last updated: 13 May 2026

Revision: 13

MedicineHumanAuthorised

INN or common name: lutetium (177Lu) chloride

Therapeutic area (MeSH): Radionuclide Imaging

Marketing authorisation issued: 6 July 2016

Last updated: 13 May 2026

Revision: 11

MedicineHumanAuthorised

Active substance: vatiquinone

Orphan designation status: Withdrawn

**Date of designation:**17 January 2018

Last updated: 13 May 2026

OrphanHuman

Active substance: vatiquinone

Orphan designation status: Withdrawn

**Date of designation:**10 December 2021

Last updated: 13 May 2026

OrphanHuman

Active substance: vatiquinone

Orphan designation status: Withdrawn

**Date of designation:**24 February 2022

Last updated: 13 May 2026

OrphanHuman